« Back to Record
Citation APA

Eggermont, A., Suciu, S., Mackie, R., Ruka, W., Testori, A., Kruit, W. H., Punt, C., Delauney, M., Sales, F., Groenewegen, G., Ruiter, D. J., Jagiello, I., Stoitchkov, K., Keilholz, U., Lienard, D., & EORTC Melanoma Group, (2005). Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet, 366(9492), 1189-1196. doi:10.1016/S0140-6736(05)67482-X


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/121872

Eggermont, A., Suciu, S., Mackie, R., Ruka, W., Testori, A., Kruit, W. H., Punt, C., Delauney, M., Sales, F., Groenewegen, G., Ruiter, D. J., Jagiello, I., Stoitchkov, K., Keilholz, U., Lienard, D., & EORTC Melanoma Group, (2005). Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet, 366(9492), 1189-1196. doi:10.1016/S0140-6736(05)67482-X